iECURE: Latest News, Top Stories & Analysis

PHILADELPHIA, PA — iECURE, Inc. recently unveiled encouraging early data from its ongoing OTC-HOPE Phase 1/2 study at the 2025 ACMG Annual Clinical Genetics Meeting. The study, which evaluates the …

Regional

iECURE to Present Promising Initial Data from Gene Editing Trial for Neonatal OTC Deficiency

March 17, 2025March 16, 2025 - by Timothy Alexander

PHILADELPHIA, PA — iECURE, Inc. has announced that early data from its Phase 1/2 OTC-HOPE clinical trial, evaluating the gene-editing candidate ECUR-506 for neonatal onset ornithine transcarbamylase (OTC) deficiency, will be …